Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report

Table 1 Laboratory Findings on Admission

WBC	6400/µl	Tp	7 g/dL	CRP	4.78 mg/dL
Neut	56.6%	Glu	123 mg/dL	Na	133 mEq/L
Lym	22.7%	ALP	164U/L	K	4.4 mEq/L
Mono	10.6%	γ-GT	40U/L	Cl	101 mEq/L
Eo	9.5%	T-bil	0.7 mg/dL
Bas	0.6%	Alb	3.8 g/dL	ESR	41 mm/h
		ALT	24U/L
RBC	444 × 10⁴/µL	AST	25 U/L	CMV-Ag	16 cells/50,000 WBC
Hb	13.8 g/dL	LDH	189U/L	(HRP-C7 method)
Ht	40.5%	Cr	1.12 mg/dL
Plt	33 × 10⁴/µL	BUN	18.2 mg/dL
		Amy	69 U/L

γ-GT gamma-glutamyl transpeptidase, Alb albumin, ALP alkaline phosphatase, ALT alanine aminotransferase, Amy amylase, AST aspartate aminotransferase, Bas basophil, BUN blood urea nitrogen, Cl chlorine, CMV-Ag cytomegalovirus antigenemia, Cr creatinine, CRP C-reactive protein, Eo eosinophil, ESR erythrocyte sedimentation rate, Glu glucose, Hb hemoglobin, Ht hematocrit, K potassium, LDH lactate dehydrogenase, Lym lymphocyte, Mono monocyte, Na sodium, Neut neutrophil, Plt platelet, RBC red blood cell, T-bil total bilirubin, TP total protein, WBC white blood cell

ISSN: 1752-1947